Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Companyâ€™s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	152M 133M 123M 113M 215M 14.48B 218M 1.46B 575M 7.14B 570M 558M 24.53B	P/E 2027 *	-	P/E 2028 *	-
Enterprise Value	129M 113M 104M 95.91M 182M 12.28B 185M 1.24B 487M 6.05B 483M 473M 20.79B	EV / Sales 2027 *	-	EV / Sales 2028 *	-
Free-Float	98.57%	Yield 2027 *	-	Yield 2028 *	-

06-16	Assertio Holdings Completes Merger With Zydus Lifesciences	MT
06-16	Assertio Holdings, Inc. Announces Board and Committee Changes, Effective June 16, 2026	CI
06-15	Assertio Holdings, Inc.(NasdaqCM:ASRT) dropped from S&P TMI Index	CI
06-15	Assertio Holdings, Inc.(NasdaqGM:ASRT) dropped from NASDAQ Composite Index	CI
06-15	Zydus Worldwide DMCC completed the acquisition of Assertio Holdings, Inc..	CI
05-13	Garda Therapeutics, Inc. cancelled the acquisition of Assertio Holdings, Inc..	CI
05-13	Zydus Worldwide DMCC entered into definitive agreement to acquire Assertio Holdings, Inc. for approximately $160 million.	CI
05-13	Assertio to be acquired by Zydus Worldwide DMCC for $23.50 per share in cash	RE
05-13	Assertio Board Approves $23.50-Per-Share Sale to Zydus Worldwide DMCC	MT
05-13	Zydus to Acquire Assertio for $166.4 Million	DJ
05-08	Assertio Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-08	Assertio and Garda mutually agree to delay launch of tender offer	RE
05-05	Assertio and Garda mutually agree to postpone commencement of tender offer	RE

04-09	HC Wainwright Downgrades Assertio Holdings to Neutral From Buy, Adjusts Price Target to $18 From $35	MT
24-07-03	HC Wainwright Initiates Assertio Holdings at Buy With $4 Price Target	MT
24-03-12	Lake Street Adjusts Assertio Therapeutics' Price Target to $3 From $4, Maintains Buy Rating	MT
23-05-10	BWS Financial Adjusts Assertio Therapeutics' Price Target to $10 From $8, Keeps Buy Rating	MT
23-05-10	Lake Street Adjusts Assertio Therapeutics' Price Target to $9 From $8, Keeps Buy Rating	MT

06-16	Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027	BU
05-19	Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT	BU
05-13	Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash	BU
05-08	Assertio and Garda Mutually Agree to Delay Launch of Tender Offer	BU
05-05	Assertio and Garda Mutually Agree to Postpone Commencement of Tender Offer	BU

Director	Title	Age	Since
Ravi Yadavar BRD	Director/Board Member	26	2026-06-15
Punit Patel BRD	Director/Board Member	-	2026-06-15

Depomed Inc Stock Nasdaq

Stocks

US2499081048

Pharmaceuticals

Valuation: Depomed Inc

Latest news : Depomed Inc

Last Transcript: Depomed Inc

Analysts' recommendations: Depomed Inc

Press Releases: Depomed Inc

Quotes and Performance

Managers and Directors: Depomed Inc

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DEPOMED INC	-9.45%	+3.54%	-	-	152M
ELI LILLY AND COMPANY	-2.33%	-2.09%	+50.33%	+162.29%	1,085B
JOHNSON & JOHNSON	-0.82%	-2.30%	+62.97%	+61.11%	624B
ABBVIE INC.	-0.73%	-4.98%	+27.22%	+84.46%	442B
ROCHE HOLDING AG	+0.33%	-1.17%	+27.98%	+26.90%	332B
NOVARTIS AG	-0.02%	-2.85%	+25.27%	+44.88%	282B
ASTRAZENECA PLC	-3.89%	-11.22%	+20.78%	+26.07%	277B
NOVO NORDISK A/S	+0.66%	-1.42%	-29.26%	-39.30%	217B
AMGEN INC.	-0.06%	-2.88%	+20.98%	+61.70%	196B
GILEAD SCIENCES, INC.	-3.72%	-1.10%	+13.35%	+71.53%	167B
Average	-1.75%	-3.56%	+24.40%	+55.51%	402.44B
Weighted average by Cap.	-0.58%	-3.16%	+35.37%	+81.70%

	2027 *	2028 *
Net sales	-	-
Net income	400K 350K 323K 298K 566K 38.15M 575K 3.86M 1.51M 18.79M 1.5M 1.47M 64.61M	-
Net Debt	-	-